Table 2.

Clinical characteristics of 4 patients who developed subclinical cardiotoxicity.

Age (years)	Mean cumulative dose (mg/m2)	Number of chemotherapy cycles	Baseline LVEF (%)	Baseline troponin I levels (ng/ml)	Midstudy troponin I levels (ng/ml)	End-study troponin I (ng/ml)	Baseline BNP (ng/dl)	Midstudy BNP (ng/dl)	End-study BNP (ng/dl)	Tumor response
45	405	6	65	<0.05	<0.05	<0.05	4.9	4.9	11.7	Neoadjuvant
44	360	4	77	<0.05	<0.05	NA	6.6	4.9	NA	Neoadjuvant
32	525	6	66	<0.05	<0.05	<0.05	4.9	4.9	4.9	Stable disease
53	450	5	68	<0.05	<0.05	<0.05	4.9	4.9	4.9	Stable disease